Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma

World Journal of Surgery

Volumn 31, Issue 5, 2007, Pages 957-968

  Machens, Andreas ^a   Dralle, Henning ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; PROTEIN RET;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER GRADING; CANCER GROWTH; CHILD; CODON; CONTROLLED STUDY; DNA SCREENING; EVALUATION; EVIDENCE BASED MEDICINE; FAMILIAL CANCER; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; METHODOLOGY; ONSET AGE; PARATHYROID ADENOMA; PARATHYROID HYPERPLASIA; PHEOCHROMOCYTOMA; PROPHYLAXIS; RISK FACTOR; SIPPLE SYNDROME; STATISTICAL ANALYSIS; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

AGE FACTORS; CARCINOMA, MEDULLARY; CODON; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PENETRANCE; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 34248170296     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-006-0769-y     Document Type: Article

References (64)

1. Eng C. Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2, Hirschsprung's disease. N Engl J Med 1996;335:943-951.
2. Machens A, Dralle H. Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside. Mol Clin Endocrinol 2006;247:34-40.
3. Cohen R, Campos JM, Salaün C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. J Clin Endocrinol Metab 2000;85:919-922.
4. Machens A, Schneyer U, Holzhausen HJ, et al. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005;90:2029-2034.
5. Osamura RY, Yasuda O, Kawakami T, et al. Immunoelectron microscopic demonstration of regulated pathway for calcitonin and constitutive pathway for carcinoembryonic antigen in the same cells of human medullary carcinomas of thyroid glands. Mod Pathol 1997;10:7-11.
6. Lips CJM, Landsvater RM, Höppener JWM, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994;331:828-835.
7. Wells SA, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220:237-250.
8. Graze K, Spiler IJ, Tashjian AH, et al. Natural history of familial medullary thyroid carcinoma. Effect of a program for early diagnosis. N Engl J Med 1978;299:980-985.
9. Gagel RF, Tashjian AH, Cummings T, et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. N Engl J Med 1988;318:478-484.
10. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-856.
11. Mulligan LM, Kwok JB, Healey CS, et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-460.
12. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-376.
13. Ito S, Iwashita T, Asai N, et al. Biological properties of RET with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res 1997;57:2870-2872.
14. Iwashita T, Kato M, Murakami H, et al. Biological and biochemical properties of RET with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 1999;18:3919-3922.
15. Michiels FM, Chappuis S, Caillou B, et al. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc Natl Acad Sci USA 1997;94:3330-3335.
16. Acton DS, Velthuyzen D, Lips CJM, et al. Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Oncogene 2000;19:3121-3125.
17. Kawai K, Iwashita T, Murakami H, et al. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation. Cancer Res 2000;60:5254-5260.
18. Smith-Hicks CL, Sizer KC, Powers JF, et al. C-cell hyperplasia, pheochromocytoma, and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B. EMBO J 2000;19:612-622.
19. Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995;267:381-383.
20. Menacho IP, Koster R, van der Sloot AM, et al. RET-familial medullary thyroid carcinoma mutants Y971F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res 2005;65:1729-1737.
21. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989;95:(suppl) 2-4.
22. Heinrich S, Schäfer M, Rousson V, et al. Evidence-based treatment of acute pancreatitis. A look at established paradigms. Ann Surg 2006;243:154-168.
23. Machens A, Niccoli-Sire P, Hoegel J, et al. for the European Multiple Endocrine Neoplasia (EUROMEN) Study Group. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003;349:1517-1525.
24. Machens A, Holzhausen HJ, Thanh PN, et al. Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 2003;134:425-431.
25. Machens A, Gimm O, Hinze R, et al. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 2001;86:1104-1109.
26. Machens A, Ukkat J, Brauckhoff M, et al. Advances in the management of hereditary medullary thyroid cancer. J Intern Med 2005;257:50-59.
27. Machens A, Brauckhoff M, Holzhausen HJ, et al. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 2005;90:3999-4003.
28. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. JAMA 1996;276:1575-1579.
29. Frank-Raue K, Höppner W, Frilling A, et al. and the German Medullary Thyroid Carcinoma Study Group. Mutations of the RET protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab 1996;81:1780-1783.
30. Mulligan LM, Kwok JB, Healey CS, et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nat Genet 1994;363:458-460.
31. Schuffenecker I, Billaud M, Calender A, et al. RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 1994;3:1939-1943.
32. Heshmati HM, Gharib H, Khosla S, et al. Genetic testing in medullary thyroid carcinoma syndromes: mutation types and clinical significance. Mayo Clin Proc 1997;72:430-436.
33. Learoyd DL, Marsh DJ, Richardson AL, et al. Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2. Arch Surg 1997;132:1022-1025.
34. Brandi ML, Gagel RF, Angeli A, et al. Consensus guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671.
35. Machens A, Dralle H. DNA-based window of opportunity for curative pre-emptive therapy of hereditary medullary thyroid cancer. Surgery 2006;139:279-282.
36. Machens A, Schneyer U, Holzhausen HJ, et al. Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation. Surgery 2004;136:1083-1087.
37. Klein I, Esik O, Homolya V, et al. Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary. J Endocrinol 2001;170:661-666.
38. Simon S, et al. Multiple endocrine neoplasia 2A syndrome. Surgical management. J Pediatr Surg 2002;37:897-900.
39. Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005;353:1105-1113.
40. Eng C, Smith DP, Mulligan LM, et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995;10:509-513.
41. Jackson CE, Tashjian AH, Block MA. Detection of medullary thyroid cancer by calcitonin assay in families. Ann Intern Med 1973;78:845-852.
42. Wolfe HJ, Melvin KEW, Cervi-Skinner SJ, et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med 1973;289:437-441.
43. Berndt I, Reuter M, Saller B, et al. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 1998;83:770-774.
44. Decker RA, Peacock ML. Update on the profile of multiple endocrine neoplasia type 2a RET mutations: practical issues and implications for genetic testing. Cancer 1997;80:557-568.
45. Frohnauer MK, Decker RA. Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated?. Surgery 2000;128:1052-1057; discussion 1057-1058.
46. Leboulleux S, Travagli JP, Caillou B, et al. Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome. Influence of the stage on the clinical course. Cancer 2002;94:44-50.
47. Gill JR, Reyes-Múgica M, Iyengar S, et al. Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA: implications for therapy. J Pediatr 1996;129:459-464.
48. Oriola J, Páramo C, Halperin I, et al. Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma. Am J Med Genet 1998;78:271-273.
49. Gimm O, Ukkat J, Niederle BE, et al. Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 2004;28:1312-1316.
50. Jindrichova S, Vcelak J, Vlcek P, et al. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic. J Endocrinol 2004;183:257-265.
51. Fugazzola L, Cerutti N, Mannavola D, et al. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer. Clin Endocrinol 2002;56:53-63.
52. Dourisboure RJ, Belli S, Domenichini E, et al. Penetrance and clinical manifestations of non-hotspot germline RET mutation, C630R, in a family with medullary thyroid carcinoma. Thyroid 2005;15:668-671.
53. Siggelkow H, Melzer A, Nolte W, et al. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy. Eur J Endocrinol 2001;144:467-473.
54. Lindskog S, Nilsson O, Jannson S, et al. Phenotypic expression of a family with multiple endocrine neoplasia type 2A due to a RET mutation at codon 618. Br J Surg 2004;91:713-718.
55. Neocleous V, Passalaris T, Spanou E, et al. Description of the first two seemingly unrelated Greek Cypriot families with a common C618R RET proto-oncogene mutation. Genet Testing 2004;8:163-168.
56. Frank-Raue K, Heimbach C, Rondot S, et al. Genotype-phenotype correlation in hereditary medullary thyroid carcinoma. Dtsch Med Wochenschr 2003;128:1998-2002.
57. Brauckhoff M, Gimm O, Weiss CL, et al. Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease. World J Surg 2004;28:1305-1311.
58. Yip L, Cote GJ, Shapiro SE, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 2003;138:409-416; discussion 416.
59. Piolat C, Dyon JF, Sturm N, et al. Very early prophylactic thyroid surgery for infants with a mutation of the RET proto-oncogene at codon 634 : evaluation of the implementation of international guidelines for MEN type 2 in a single centre. Clin Endocrinol 2006;65:118-124.
60. Henry JF, Gramatica L, Denizot A, et al. Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 1998;383:167-169.
61. Frank-Raue K, Buhr H, Dralle H, et al. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 2006;155:229-236.
62. Hennekens CH, Buring JE. (1987) Epidemiology in Medicine. Little, Brown and Company, Boston/Toronto.
63. Friedman LM, Furberg CD, DeMets DL. (1998) Fundamentals of Clinical Trials. Springer-Verlag, New York.
64. Schuffenecker I, Ginet N, Goldgar D, et al. Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Groupe D'Etude des Tumeurs à Calcitonine. Am J Hum Genet 1997;60:233-237.